European Journal of Nanomedicine
Editor-in-Chief: Hunziker, Patrick / Mollenhauer, Jan
Managing Editor: Löffler, Beat / Salieb-Beugelaar, Georgette
Editorial Board Member: Alexiou, Christoph / Balogh, Lajos / Barenholz, Yechezkel / Dawson, Kenneth / Fadeel, Bengt / Jordan, Andreas / Lee, Dong Soo / Lehr, Claus-Michael / Müller, Bert / Scoles, Giacinto / Serruys, Patrick / Szebeni, Janos
SCImago Journal Rank (SJR) 2014: 0.288
Source Normalized Impact per Paper (SNIP) 2014: 0.245
Impact per Publication (IPP) 2014: 0.750
- Submission of Manuscripts
- Abstracting & Indexing
- Editorial Information
- More ...
- Comments (0)
Free Trial Access Available!
We offer to our European Journal of Nanomedicine authors the following advantages:
• No page charges
• Color figures without any additional fee
• Free-of-charge front cover exposure of excellent contributions by Editor´s choice
• Online publication ahead of print
Aims and Scope
The European Journal of Nanomedicine (EJNM) focuses on the spectrum from nano(bio)technological engineering and characterization to clinically translatable innovative prevention, diagnostics, and therapies of major as well as neglected human diseases. Thus, the readership is multidisciplinary, including scientists in chemistry, physics, engineering, pharmacology, molecular biology, biomedicine, and clinicians, addressing recipients in academic, industrial, and regulatory environments, the informed public and policymakers.
Main topics covered are: Experimental, Analytical, (Pre-)Clinical, Preventive and Therapeutic Nanomedicine, Medical Nanomaterials, Nanobiotechnology, Nanodiagnostics, Nanotoxicity, Nano-Imaging Technologies, Vanguard Nano-Technologies, Implementation and Implications of Nanomedicine, Personalized Nanomedicine.
- Type of Publication:
Physicians Applying Nanoscience and Biomedicine, Chemists, Physicists, Biologists, Engineers in Research and Industry, Policy Makers
Instructions for Authors
Instructions for Authors
European Journal of Nanomedicine (EJNM)
(last update: April 30th 2014)
Aims and Scope
The European Journal of Nanomedicine (EJNM) is a peer-reviewed journal dedicated to basic and clinical research in Nanomedicine. Its focus lies on the clinical application of nanoscience tools, methods and materials and on the exploration of the implications of Nanomedicine.
EJNM publishes Original Articles, Reviews, Short Communications, Opinion Papers, and Letters to the Editor.
Manuscripts are independently reviewed by peers selected by the Editors. Decisions are reached as quickly as possible. EJNM aspires to notify authors within 4 weeks from submission date. When manuscripts are accepted subject to revision, the revised manuscript should be returned within 6 weeks. Accepted papers are promptly published online ahead-of-print as soon as they have been finally processed.
Submission of a manuscript to EJNM implies that the work described is not copyrighted, published or submitted elsewhere, except in abstract form. The corresponding author should ensure that all authors approve the manuscript before its submission to EJNM.
is restricted to those who have made a significant contribution to the conceptual design of the study, the execution of the study.
Ethical conduct of research
The authors must describe and confirm safeguards to meet ethical standards. The ethics statements for the European Journal of Nanomedicine are based on the Committee on Publication Ethics (COPE) Best Practice Guidelines for Journal Editors (cf. http://publicationethics.org/) and the "Uniform Requirements for Manuscripts (URM) Submitted to Biomedical Journals" of the International Committee of Medical Journal Editors (ICMJE – http://www.icmje.org/).
Where applicable, all authors must confirm in writing that they have complied with the World Medical Association Declaration of Helsinki (cf.http://www.wma.net/en/30publications/10policies/b3/) regarding ethical conduct of research involving human subjects and/or animals. In the Materials and Methods Section, or in a separate section, the manuscript should contain a statement that the study has been approved by the Ethical Committee of the institution where the study was performed, and that the study subjects, or their legal guardians, gave informed consent for participation in the study.
For background information on our publication ethics please visit: http://www.degruyter.com/view/supplement/s1662596X_Publication_Ethics_and_Malpractice_Statement.pdf
Conflict of interest
When authors submit a manuscript, they are responsible for recognizing and disclosing financial and/or other conflicts of interest that might bias their work and/or could inappropriately influence his/her judgment. If no specified acknowledgement is given, the Publishers assume that no conflict of interest exists.
Manuscripts are accepted on condition of transfer of copyright (for U.S. government employees: to the extent transferable) to EJNM. Once the manuscript is accepted, it may not be published elsewhere without the consent of the copyright holders.
Manuscripts should be submitted in electronic form to our online submission, peer review and production system at
Preparation of manuscripts
Manuscripts should be written in clear and concise English. Please have your text proofread by an English native speaker before you submit it for consideration. At the proof stage, only minor changes other than corrections of printers’ errors are allowed.
Authors are asked to follow the recommendations of the
Système International d’Unités (SI)
General format and length
Please avoid footnotes in the text, use parentheses instead. Original articles should not exceed 6,000 words, including references, and should not occupy more than 7- 10 printed pages (one printed page is approx. 4000 characters). Communications should not exceed 3 printed pages. Each full page of printed text corresponds to approximately 800 words. Allow space for tables and illustrations within the page limit (each table or illustration accounts usually for approx. a half printed page).
should have Title page, Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Acknowledgements and List of non-standard abbreviations (if applicable), References, Table and Figure Legends, if applicable.
Original Articles and Reviews should be submitted along with a photograph and a short biography (6-10 lines, written in 3rd person) of the corresponding author and all co-author(s). This information will be published after the References.
An eye-catching graphic for the Table of Contents (5 cm wide and 5 cm high) should be provided at the end of each manuscript along with a max. length of 30 words with a text different from the abstract. This text should show the attraction points of your work.
Reference lists have to be written in Vancouver style, please see:
The names of journals should be abbreviated according to the World List of Scientific Periodicals.
Number the references consecutively in the order in which they appear in the text, including tables and figures. In the body-text, identify references by Arabic numerals in round brackets (1). In the references all authors must be included; et al. is not accepted. Do not use italic font in the reference section.
If you use a reference managing program you could apply the New England Journal of Medicine style to your manuscript
For more detailed information please see: http://guides.lib.monash.edu/content.php?pid=346637&sid=3171016
Submit tables on separate pages and number them consecutively using Arabic numerals. Provide a short descriptive title, column headings, and (if necessary) footnotes to make each table self-explanatory. Refer to tables in the text as Table 1, etc. Use Table 1, etc. in the table legends. Please indicate in the manuscript the approximate position of each table.
Illustrations will be reduced in size to fit, whenever possible, the width of a single column. Lettering in all figures within the article should be uniform in style, preferably a sans serif typeface, and of sufficient size, so that it is readable at the final size of approximately 2 mm. Uppercase letters A, B, C, etc. should be used to identify parts of multi-part figures. Cite all figures in the text in a numerical order. Indicate the approximate position of each figure. Refer to figures in the text as Figure 1, etc. Use Figure 1, etc. in the figure legends. Please note that if any of the figures you used are copyrighted, you need to obtain permission from the copyright owners to reproduce these figures in EJNM. You also need to document the copyright permission in the respective figure legend.
Authors are encouraged to submit illustrations in color if necessary for their scientific content. Publication of color figures is provided free of charge both in online and print editions.
Line drawings and photographs must be of high quality. Please note that faint shading may be lost upon reproduction.
Provide a short descriptive title, and (if necessary) footnotes to make each figure self-explanatory on separate pages. Explain all symbols used in the figures. Remember to use the same abbreviations as in the body-text.
The electronic files of typeset articles in Adobe Acrobat PDF format are provided free of charge; corresponding authors receive notification that their article has been published online with a link to DeGruyter Author Services, where they can pick up their authors’ copy. Paper offprints can be ordered in addition at the time of submission or at the page proof stage.
Note for authors of NIH-funded research
Walter de Gruyter Publishers acknowledge that the author of an NIH-funded article retains the right to provide a copy of the final manuscript to NIH upon acceptance for publication or thereafter, for public archiving in PubMed Central 12 months after publication in EJNM note that only the accepted author's version of the manuscript, not the PDF file of the published article, may be used for NIH archiving.
Please contact the Editorial Office for any further questions:
European Journal of Nanomedicine - Editorial Office
Alexandra Hinz – Managing Editor
Genthiner Straße 13
10785 Berlin, Germany
Tel. +49-30-26005-358 / Fax: +49-30-26005-325
European Journal of Nanomedicine is covered by the following services:
- Baidu Scholar
- Chemical Abstracts Service (CAS)
- Chemical Abstracts Service (CAS) - SciFinder
- CNKI Scholar (China National Knowledge Infrastructure)
- EBSCO (relevant databases)
- EBSCO Discovery Service
- Elsevier - Compendex
- Elsevier - Engineering Village
- Elsevier - SCOPUS
- Genamics JournalSeek
- Google Scholar
- Meta (formerly Sciencescape)
- Naviga (Softweco)
- Polymer Library
- Primo Central (ExLibris)
- ProQuest (relevant databases)
- SCImago (SJR)
- Summon (Serials Solutions/ProQuest)
- TDOne (TDNet)
- Ulrich's Periodicals Directory/ulrichsweb
- WorldCat (OCLC)
Patrick Hunziker, University Hospital Basel, Switzerland
Jan Mollenhauer, University of Southern Denmark, Odense, Denmark
Scientific Managing Editor
Georgette B. Salieb-Beugelaar, University Hospital Basel, Switzerland
Managing Editor CLINAM
Beat Löffler, European Foundation for Clinical Nanomedicine, Basel, Switzerland
Christoph Alexiou, University Hospital Erlangen, Germany
Yechezkel Barenholz, The Hebrew University of Jerusalem, Israel
Kenneth Dawson, University College Dublin, Ireland
Rutledge Ellis-Behnke, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
Bengt Fadeel, Karolinska Institute, Stockholm, Sweden
Silke Krol, Neurological Institute Foundation Carlo Besta, Milan, Italy
Dong Soo Lee, Seoul National University, Seoul, South Korea
Claus-Michael Lehr, Saarland University, Saarbrücken, Germany
Eder Lilia Romero, Quilmes National University, Bernal, Buenos Aires, Argentina
Simó Schwartz, Vall d'Hebron University Hospital, Barcelona, Spain
Janos Szebeni, Semmelweis University, Budapest, Hungary
Ghaleb Husseini, American University of Sharjah, Sharjah, United Arab Emirates
Harald Mangge, Medical University of Graz, Graz, Austria
Bert Müller, University of Basel, Switzerland
Dan Peer, Tel Aviv University, Tel-Aviv, Israel
Giacinto Scoles, Princeton University, Princeton, New Jersey, USA
Patrick W. Serruys, Erasmus University Medical Center, Rotterdam, The Netherlands
Lajos Balogh, AA Nanomedicine & Nanotechnology Consultants, Boston, Massachusetts, USA
Genthiner Straße 13
10785 Berlin Germany
T +49- 30- 26005- 358
F +49- 30- 26005- 325